Clinical Significance of Fasting Glucose Criteria in Metabolic Syndrome

Kyong Soo Park

doi:10.5124/jkma.2005.48.12.1173

J Korean Med Assoc > Volume 48(12); 2005 > Article

Park: Clinical Significance of Fasting Glucose Criteria in Metabolic Syndrome

Special Issue

Metabolic Syndrome

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2005; 48(12): 1173-1178.

Published online: December 31, 2005

DOI: http://dx.doi.org/10.5124/jkma.2005.48.12.1173

Clinical Significance of Fasting Glucose Criteria in Metabolic Syndrome

Kyong Soo Park, M.D.

Department of Internal Medicine, Seoul National University College of Medicine & Hospital, Korea. kspark@snu.ac.kr

Abstract

Both Adult Treatment Panel III(ATP III) and International diabetes Federation(IDF) adopted impaired fasting glucose (IFG) as one of the criteria for identifying individuals with metabolic syndrome. However, many studies have shown that IGT is a better predictor of cardiovascular disease(CVD) than IFG. Recently the American Diabetes Association(ADA) revised the diagnostic criteria for IFG, lowering the diagnostic threshold from 110 mg/dL to 100 mg/dL to improve the alignment of IFG and IGT. Although the revised definition of IFG increases the prevalence of metabolic syndrome as well as that of IFG, relative risk of CVD is still lower than that of IGT. The clinical and public health implications of the revised IFG definition remain to be elucidated.

Impaired Fasting Glucose(IFG); Impaired Glucose Tolerance(IGT); Metabolic Syndrome; Cardiovascular Risk

References

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.

2. WHO. Definition, diagnosis and classification of diabetes mellitus and its complication. Report of a WHO consultation 1999.

3. National Institutes of Health. NIH publication No. 01 - 3670. Third report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults(Adult Treatment Panel III). Executive summary 2001.

4. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-1062.

5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:Suppl 1. 1183-1197.

6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;260:Suppl 1. S5-S20.

7. DECODE Study Group. the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.

8. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-924.

9. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Eschwege E, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-367.

10. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Heine RJ, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931.

11. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies Arch Intern Med 2004;164:2147-2155.

12. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Brownlee M, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049-1057.

13. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497.

14. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 2004;25:153-175.

15. Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Tan CE, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-1734.

16. Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen B, Gao W, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004;47:1396-1402.

17. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005;181:143-148.

18. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.

Clinical Significance of Fasting Glucose Criteria in Metabolic Syndrome

Abstract

References

Figure 1